09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
3.
MYELOID-DERIVED GROWTH FACTOR FOR USE IN TREATING OR PREVENTING A LIVER DISORDER
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating or preventing a liver disorder. The present invention also relates to vectors comprising the nucleic acid, host cells expressing the nucleic acid, and methods for use in treating a liver disorder.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
7.
PROCESS FOR PURIFYING AND ENRICHING PROTEINS, NUCLEIC ACIDS OR VIRUSES USING AN AQUEOUS TWO-PHASE SYSTEM
The invention relates to a method for purifying and enriching a target product selected from
immunoglobulins or other proteins; or
plasmid DNA, genomic DNA, RNA or other nucleic acids or viruses, wherein the measured electrical conductivity values and/or the measured turbidity values of the phases are used for adjusting the position of the phases in a separating device (10, 100) and for separating the phases. The invention also relates to a device for carrying out the method and to the use thereof.
The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of cardiovascular diseases; providing medical and scientific
research information in the field of cardiovascular
diseases.
11.
PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present invention relates to methods for using soluble guanylate cyclase (sGC) activators for preventing, slowing the progression of, delaying or treating clinically significant portal hypertension (CSPH) and decompensated cirrhosis due to non-cholestatic liver disease.
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I),
Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I),
Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I),
wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
18.
Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.
This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I):
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I):
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I):
and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (I) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.
The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), their use as degraders of SMARCA, pharmaceutical compositions which contain PROTACs of this kind and their medical uses, especially as agents for treatment and/or prevention of oncological diseases.
The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), their use as degraders of SMARCA, pharmaceutical compositions which contain PROTACs of this kind and their medical uses, especially as agents for treatment and/or prevention of oncological diseases.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The invention provides a method of suppressing gene expression, comprising providing a mammalian cell with a suppression target RNA molecule comprising a heterologous RNAi target site operatively linked to a RNA sequence from a gene of interest, or with a DNA encoding said suppression target RNA molecule; providing to the cell an inhibitory RNA that has a complementary nucleotide sequence to the heterologous RNAi target site; wherein binding of the inhibitory RNA to the heterologous RNAi target site suppresses gene expression of the operatively linked RNA sequence from the gene of interest; and wherein said heterologous RNAi target site has a size of at least 18 nucleotides in length. The invention further provides nucleic acids and cells suitable for such a method.
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
25.
PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinyIpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The subject technology relates to a cell retention device and method for use in a perfusion cell culture system where the cell retention device includes a hollow-fiber filter having an average pore size ranging from about 0.5 to about 20 μm and having the ability to operate under perfusion cell culture conditions for up to 35 days without being clogged or losing its product sieving ability by more than 20%.
The present invention relates to compounds of formula (I):
The present invention relates to compounds of formula (I):
The present invention relates to compounds of formula (I):
or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
ciscis-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.
The invention concerns an oral pharmaceutical composition consisting essentially of
the PDE4B-inhibitor of formula III
The invention concerns an oral pharmaceutical composition consisting essentially of
the PDE4B-inhibitor of formula III
in the dose of 18 mg or 9 mg and
optionally of one or more pharmaceutically acceptable carriers or excipients
for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily.
The invention concerns an oral pharmaceutical composition consisting essentially of
the PDE4B-inhibitor of formula III
in the dose of 18 mg or 9 mg and
optionally of one or more pharmaceutically acceptable carriers or excipients
for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily.
The invention further concerns oral pharmaceutical compositions comprising the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and a therapeutically effective dose of a second active ingredient selected from nintedanib or pirfenidone, wherein these oral pharmaceutical compositions are administered to the patient twice daily.
A cartridge and a nebulizer for nebulizing a fluid as well as a method for fluidically connecting the cartridge to the nebulizer are proposed. The cartridge comprises a closure with a valve, wherein the valve displaces fluid into the nebulizer when opened. Further, the cartridge forms two axially spaced sealings with the nebulizer when connected.
The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The invention concerns an oral pharmaceutical composition comprising
either 18 mg or 9 mg of the PDE4B-inhibitor of formula III
The invention concerns an oral pharmaceutical composition comprising
either 18 mg or 9 mg of the PDE4B-inhibitor of formula III
a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and
optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily.
The invention concerns an oral pharmaceutical composition comprising
either 18 mg or 9 mg of the PDE4B-inhibitor of formula III
a therapeutically effective dose of a second active agent selected from the group consisting of nintedanib or pirfenidone and
optionally, one or more pharmaceutically acceptable carriers or excipients for the treatment of a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD), wherein this oral pharmaceutical composition is to be administered to said patient twice daily.
The invention further concerns the use of the PDE4B-inhibitor of formula III for preparing an oral pharmaceutical composition comprising either 18 mg or 9 mg of the PDE4B-inhibitor of formula III for use in a method of treating a patient suffering from one or more Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), wherein said oral pharmaceutical composition is to be orally administered twice daily to said patient in combination with a therapeutically effective amount of a therapeutically effective dose of a second active agent selected from the group consisting of nintdanib and pirfenidone.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61P 11/00 - Drugs for disorders of the respiratory system
37.
SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
The present invention encompasses compounds of formula (I)
The present invention encompasses compounds of formula (I)
The present invention encompasses compounds of formula (I)
wherein R1a, R1b, R2a, R2b, Z, R3 to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Shown and described is a holding device (1) for a dispensing device (2), in particular for an autoinjector, for substance dispensing at least one therapeutically and/or diagnostically effective substance. According to the invention, it is provided that the holding device (1) is embodied as a multi-holder for holding two or more dispensing devices (2) on the holding device (1) and, in the state of holding the dispensing devices (2), for substance dispensing via at least one dispensing device (2) held on the holding device (1).
The present invention relates to compounds of formula I
The present invention relates to compounds of formula I
The present invention relates to compounds of formula I
a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an association with the function of metabotropic glutamate receptor subtype 4 (mGluR4). A, R1, R2, R3, R4, R5 and R6 have meanings given in the description.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to compounds of formula (I)
The present invention relates to compounds of formula (I)
The present invention relates to compounds of formula (I)
for use in methods for of a patient with a disorder associated with bacterial or fungal severe sepsis, and bacterial or fungal septic shock and conditions arising therefrom, wherein the groups Y, A and R1 to R7 are as defined herein, pharmaceutical compositions which contain compounds of this kind and their use as medicaments for the treatment of bacterial or fungal severe sepsis and bacterial or fungal septic shock and conditions arising therefrom.
The present invention relates to the treatment of generalized pustular psoriasis (GPP), including the treatment and prevention of flares in adults and adolescents from 12 years of age with a history of generalized pustular psoriasis (GPP) with anti-IL36R antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention relates to the treatment of generalized pustular psoriasis (GPP), including the treatment and prevention of flares in adults and adolescents from 12 years of age with a history of generalized pustular psoriasis (GPP) with anti-IL36R antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The General Hospital Corporation d/b/a Massachusetts General Hospital (USA)
Inventor
Herrmann, Franziska Elena
Le, Quang Huy
Seither, Peter
Medoff, Benjamin D.
Moutinho Dos Santos, Daniela Vanessa
Yang, Yang
Abstract
Methods of treating and preventing fibrosis, and diseases/disorders characterised by fibrosis, through ADAMTS14 inhibition are disclosed, as well as agents for use in such methods.
The present invention relates to a method of determining the responsiveness of a cancer patient to a treatment with a compound inhibiting KRAS protein or a mutant of a KRAS protein, or to a treatment with a compound inhibiting the interaction between MDM2 and p53, the method comprising measuring the level of Survivin in a first sample obtained from the patient prior to treatment with the compound, measuring the level of Survivin in a second sample obtained from said patient during or after treatment with the compound, comparing the level of Survivin in said second sample with the level of Survivin in said first sample, wherein the patient is determined to be responsive to the treatment with said compound when the level of Survivin in the second sample is decreased as compared to the level of Survivin in the first sample. The present invention further relates to the use of Survivin in a method for determining the ability of a compound to inhibit KRAS protein or a mutant of a KRAS protein, or of a compound inhibiting the interaction between MDM2 and p53, or of a pharmaceutical formulation comprising said compound inhibiting KRAS protein or a mutant of a KRAS protein or said compound inhibiting the interaction between MDM2 and p53, to treat cancer.
The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure is directed to a method (a) for the quantification of polysorbate in aqueous formulations containing polysorbate and one or more (poly)peptides having the following steps: (a.1) providing a sample of the aqueous formulation; (a.2) adding of a solution containing the fluorescent dye N-phenyl-1-naphthylamine to the sample of step (a.1) to obtain a fluorescent dye containing sample to be tested in a fluorescence micelle assay; (a.3) optionally incubating the fluorescent dye containing sample of step (a.2); (a.4) performing a fluorescence micelle assay with the fluorescent dye containing sample obtained in step (a.2) or step (a.3) and (a.5) determining the content of polysorbate present in the sample from the fluorescence micelle assay performed in step (a.4); with the proviso that the method is being performed without the use of a HPLC-system. An additional method (b) of the present invention also allows a high-throughput-screening of a great number of samples. The presence of (poly)peptide(s) does/do not interfere with the fluorescence micelle assay measurement in any way.
The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anti-IL-36R) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The invention generally relates to the treatment of cancer by using DLL3/CD3 binding proteins In particular, the present invention relates to uses and methods of using DLL3/CD3 binding proteins in a dosage and administration regimen for the treatment of cancer.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
55.
FORMULATIONS TO STABILIZE VIRUS-BASED THERAPEUTICS
The present invention relates to determining a color value or corresponding property of a protein-containing solution or of a protein-containing product prepared therefrom, comprising exciting fluorescent radiation of the solution or product, measuring at least one property, preferably a spectrum or corresponding feature, of the fluorescent radiation, and determining, based on a correlation between the at least one property of the fluorescent radiation and the color value or corresponding property, the present or future color value or corresponding property of the solution or product.
The invention generally relates to the treatment of cancer by using DLL3/CD3 binding proteins. In particular, the present invention relates to uses and methods of using DLL3/CD3 binding proteins in a dosage and administration regimen for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates in general to the formulation of antibodies and antigen-binding fragments thereof. In order to address a need for formulations for new antibodies that are able to be administered by different routes as well as in low and high dosage a formulation comprising an antibody or antigen-binding fragment thereof is provided, as well as uses of the formulation and methods involving the formulation.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
62.
7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE FOR USE IN THE TREATMENT OF BORDERLINE PERSONALITY DISORDER
The present invention relates to 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3- (trifluoromethoxy)-phenoxy)-3,7-dihydro-1H-purine-2,6-dione (Compound 1) or a pharmaceutical composition comprising Compound 1 for the use in the prevention or treatment of Borderline Personality Disorder (BPD).
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of metabolic disease; providing medical and scientific research information in the field of metabolic disease
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Medical and scientific research in the fields of metabolic diseases, providing medical and scientific research information in the field metabolic diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Medical and scientific research in the fields of metabolic diseases; providing medical and scientific research information in the field metabolic diseases.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the field of inflammatory
diseases; providing medical and scientific research
information in the field of inflammatory diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of metabolic
diseases; providing medical and scientific research
information in the field metabolic diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of metabolic
diseases, providing medical and scientific research
information in the field metabolic diseases.
73.
SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS
The present invention encompasses compounds of formula (I)
The present invention encompasses compounds of formula (I)
The present invention encompasses compounds of formula (I)
wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 211/04 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
The present invention relates to the treatment of or alleviation of signs and symptoms of GPP or an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-interleukin-36R (anti-IL36R) antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of metabolic diseases; providing medical and scientific
research information in the field of metabolic diseases.
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,
wherein
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1,
and prodrugs or pharmaceutically acceptable salts of these compounds
for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
85.
TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA
The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score.
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
86.
ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
The present invention relates to a dosing schedule of a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular to its doses and second or further line administration.
The present disclosure provides [1,3]thiazolo[4,5-d]-pyrimidon-7-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
The present disclosure provides [1,3]thiazolo[4,5-d]-pyrimidon-7-ones that are inhibitors of NOX4, and are therefore useful for the treatment of diseases treatable by inhibition of NOX4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
The present invention relates to anti-IL1RAP binding compounds, in particular new anti-IL1RAP antibodies and therapeutic and diagnostic methods and compositions for using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
90.
USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF INFLAMMATORY CONDITIONS
The present invention relates to anti-CD40 antibodies and therapeutic methods for using the same for treating and/or preventing autoimmune or inflammatory diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention concerns new crystalline forms of the PDE4B-inhibitor of formula (I) in particular the Dehydrated Monohydrate Form IV which shows reflex peaks in the X-ray powder diffraction diagram with the following 2Theta-values measured using CuKα radiation: 4.6 ±0.2, 13.9 ±0.2, 19.6 ±0.2 and 23.8 ±0.2, the Anhydrous "high temperature" Form V which shows reflex peaks in the X-ray powder diffraction diagram with 2Theta-values measured using CuKα radiation: 4.8 ±0.2, 9.8 ±0.2, 19.6 ±0.2, 17.0 ±0.2, 21.2 ±0.2 and 26.2 ±0.2, the Monohydrate Form VI which shows reflex peaks in the X-ray powder diffraction diagram with 2Theta-values measured using CuKα radiation: 4.6 ±0.2, 18.7 ±0.2, 19.6 ±0.2, 21.7 ±0.2 and 26.4 ±0.2, and the Dihydrate Form VII which shows reflex peaks in the X-ray powder diffraction diagram with 2Theta-values measured using CuKα radiation: 4.31 ±0.2, 8.64 ±0.2, 12.99 ±0.2 and 19.11 ±0.2.
Formulations comprising polysorbate and citrate are disclosed. Also disclosed are uses of citrate to prevent degradation of polysorbate in an aqueous formulation and methods for preparing a composition, for example a composition comprising peptide/polypeptide for use in therapy, prophylaxis and/or diagnosis.
The present disclosure provides certain phenylpiperidine derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
100.
PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain phenylpiperidine derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
